+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control



Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control



Cancer Research 66(9): 4835-4842



We have previously developed an oncolytic herpes simplex virus-1 based on a clinical virus isolate, which was deleted for ICP34.5 to provide tumor selected replication and ICP47 to increase antigen presentation as well as tumor selective virus replication. A phase I/II clinical trial using a version of this virus expressing granulocyte macrophage colony-stimulating factor has shown promising results. The work reported here aimed to develop a version of this virus in which local tumor control was further increased through the combined expression of a highly potent prodrug activating gene [yeast cytosine deaminase/uracil phospho-ribosyltransferase fusion (Fcy::Fur)] and the fusogenic glycoprotein from gibbon ape leukemia virus (GALV), which it was hoped would aid the spread of the activated prodrug through the tumor. Viruses expressing the two genes individually or in combination were constructed and tested, showing (a) GALV and/or Fcy::Fur expression did not affect virus growth; (b) GALV expression causes cell fusion and increases the tumor cell killing at least 30-fold in vitro and tumor shrinkage 5- to 10-fold in vivo; (c) additional expression of Fcy::Fur combined with 5-fluorocytosine administration improves tumor shrinkage further. These results indicate, therefore, that the combined expression of the GALV protein and Fcy::Fur provides a highly potent oncolytic virus with improved capabilities for local tumor control. It is intended to enter the GALV/Fcy::Fur expressing virus into clinical development for the treatment of tumor types, such as pancreatic or lung cancer, where local control would be anticipated to be clinically advantageous.

(PDF emailed within 0-6 h: $19.90)

Accession: 048578074

Download citation: RISBibTeXText

PMID: 16651439

DOI: 10.1158/0008-5472.CAN-05-4352


Related references

Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control. Methods in Molecular Biology 542: 551-564, 2009

Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Molecular Therapy 7(6): 748-754, 2003

Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Molecular Therapy 9(5): 658-665, 2004

Sequence of a fusogenic herpes simplex virus, RH2, for oncolytic virotherapy. Journal of General Virology 94(Pt 4): 726-737, 2013

A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma. Virology Journal 8: 294-294, 2011

ICP345 deleted Herpes Simplex Virus 1 with enhanced oncolytic and anti-tumor potential Development of novel replicating vectors for tumor therapy. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1097, March, 2002

Enhanced antitumoral activitiy of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. 2012

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proceedings of the National Academy of Sciences of the United States of America 98(11): 6396-6401, 2001

Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. International Journal of Cancer 132(7): 1592-1601, 2013

Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 60(1): 53-60, 2004

Fusogenic domains in herpes simplex virus type 1 glycoprotein H. Journal of Biological Chemistry 280(31): 28632-28643, 2005

Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clinical Cancer Research 12(2): 643-652, 2006

Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Research 58(24): 5731-5737, 1998

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. Virology Journal 5(): 68-68, 2008

A fusogenic segment of glycoprotein H from herpes simplex virus enhances transfection efficiency of cationic liposomes. Journal of Gene Medicine 10(6): 646-654, 2008